Shibata, Mamoru http://orcid.org/0000-0002-2416-4259
Nihira, Atsuko
Tanji, Yuka
Ozeki, Akichika
Imagawa, Hideyuki
Komori, Mika
Clinical trials referenced in this document:
Documents that mention this clinical trial
Clinical Evaluation After Discontinuation of Galcanezumab in Japanese Patients with Episodic and Chronic Migraine: Analysis of a Randomized, Placebo-Controlled Trial and Open-label Extension Study
https://doi.org/10.1007/s40120-024-00602-z
Galcanezumab Efficacy Through the Dosing Interval in Japanese Patients with Episodic Migraine: Post Hoc Analysis of a Phase 2 Randomized Trial
https://doi.org/10.1007/s40120-023-00534-0
Galcanezumab Effects on Migraine Severity and Symptoms in Japanese Patients with Episodic Migraine: Secondary Analysis of a Phase 2 Randomized Trial
https://doi.org/10.1007/s40120-022-00410-3
Treatment Satisfaction of Galcanezumab in Japanese Patients with Episodic Migraine: A Phase 2 Randomized Controlled Study
https://doi.org/10.1007/s40120-021-00236-5
Funding for this research was provided by:
Eli Lilly Japan
Daiichi-Sankyo
Article History
Received: 19 June 2023
Accepted: 10 August 2023
First Online: 12 September 2023
Declarations
:
: Mamoru Shibata and Atsuko Nihira have received honoraria from Amgen K.K., Daiichi Sankyo Company, Limited, Eli Lilly Japan K.K., and Otsuka Pharmaceutical Co., Ltd. Yuka Tanji, Akichika Ozeki, Hideyuki Imagawa, and Mika Komori are employees of Eli Lilly Japan K.K. and minor shareholders in Eli Lilly and Company.
: The protocol was approved by the local institutional review boards (Table S1). All patients provided written informed consent before any study procedures. The study was conducted in accordance with the Declaration of Helsinki, Good Clinical Practice, and the Council for International Organizations of Medical Sciences’ <i>International Ethical Guidelines for Health-related Research Involving Humans</i>.